Paradigm Asset Management Co. LLC Buys 352,400 Shares of Haleon PLC Sponsored ADR $HLN

Paradigm Asset Management Co. LLC raised its stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 7,466.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 357,120 shares of the company’s stock after purchasing an additional 352,400 shares during the quarter. Paradigm Asset Management Co. LLC’s holdings in Haleon were worth $1,800,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of HLN. Brighton Jones LLC bought a new stake in Haleon during the fourth quarter valued at approximately $187,000. AQR Capital Management LLC lifted its position in Haleon by 22.5% during the first quarter. AQR Capital Management LLC now owns 96,323 shares of the company’s stock valued at $991,000 after purchasing an additional 17,720 shares during the last quarter. Focus Partners Wealth lifted its position in Haleon by 7.6% during the first quarter. Focus Partners Wealth now owns 73,106 shares of the company’s stock valued at $752,000 after purchasing an additional 5,178 shares during the last quarter. Geneos Wealth Management Inc. lifted its position in Haleon by 33.0% during the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after purchasing an additional 1,203 shares during the last quarter. Finally, CW Advisors LLC lifted its position in Haleon by 11.6% during the second quarter. CW Advisors LLC now owns 25,075 shares of the company’s stock valued at $260,000 after purchasing an additional 2,601 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors.

Haleon Stock Up 1.4%

Shares of NYSE HLN opened at $9.11 on Wednesday. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47. Haleon PLC Sponsored ADR has a 52 week low of $8.71 and a 52 week high of $11.42. The firm’s fifty day moving average is $9.84 and its 200 day moving average is $9.97. The company has a market cap of $40.47 billion, a price-to-earnings ratio of 23.35, a PEG ratio of 2.04 and a beta of 0.15.

Haleon (NYSE:HLN) last issued its earnings results on Saturday, February 14th. The company reported $6.32 EPS for the quarter. The firm had revenue of $3.65 billion during the quarter. On average, equities research analysts expect that Haleon PLC Sponsored ADR will post 0.56 earnings per share for the current year.

Haleon Announces Dividend

The company also recently announced a dividend, which will be paid on Thursday, May 14th. Investors of record on Friday, April 10th will be paid a $0.1307 dividend. This represents a dividend yield of 266.0%. The ex-dividend date of this dividend is Friday, April 10th. Haleon’s payout ratio is presently 64.10%.

Analyst Ratings Changes

HLN has been the subject of several research analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a research report on Thursday, January 22nd. HSBC upgraded shares of Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Argus upgraded shares of Haleon to a “strong-buy” rating in a report on Tuesday, March 17th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Haleon in a report on Thursday, April 30th. Finally, Wall Street Zen upgraded shares of Haleon from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Haleon presently has a consensus rating of “Moderate Buy” and an average price target of $13.40.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.